• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Canadian Respiratory Journal >Intrabullous Adhesion Pexia (IBAP) by Percutaneous Pulmonary Bulla Centesis: An Alternative for the Surgical Treatment of Giant Pulmonary Bulla (GPB)
【24h】

Intrabullous Adhesion Pexia (IBAP) by Percutaneous Pulmonary Bulla Centesis: An Alternative for the Surgical Treatment of Giant Pulmonary Bulla (GPB)

机译：经皮肺大泡穿刺术小管内黏附性缺氧（IBAP）：外科治疗巨肺大泡（GPB）的替代方法

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and Objective. Most patients with giant pulmonary bulla (GPB) are treated by surgery; however, there is a subset for whom surgery is not a viable option, such as those with contraindications, or those unwilling to undergo operation. Therefore, an alternative minimally invasive method is desired for this subpopulation. The aim of this study was to explore an alternative procedure for treating GPB. Methods. This was a prospective, nonrandomized, single-arm, unblinded study evaluating the efficacy and safety of intrabulla adhesion pexia (IBAP) procedure in GPB patients. The study was conducted between December 2004 and April 2017. Results. There were 38 cases in 36 patients (33 males and 3 females) with the target GPB cavities varying in size (range, 10?cm × 7?cm × 5?cm to 15?cm × 8?cm × 30?cm (anteroposterior diameter × medial-lateral diameter × superoinferior diameter)). After IBAP treatment, the closure ratio of GPB in one month was 86.84% (33/38), while the dyspnea index significantly decreased from 4.11 ± 1.11 to 2.24 ± 1.15 (). In addition, the mean FEV1 (L) increased from 1.06 ± 0.73 to 1.57 ± 1.13 (), while RV (L) decreased from 2.77 ± 0.54 to 2.36 ± 0.38 () and TLC (L) decreased from 6.46 ± 1.21 to 5.86 ± 1.08 (). Moreover, PaO2 (mmHg) increased from 52.18 ± 8.31 to 68.29 ± 12.34, while the 6 MWD increased by 129.36% from 131.58 ± 105.24 to 301.79 ± 197.90 (). Collectively, these data indicated significant improvement in pulmonary function and exercise tolerance after IBAP treatment. Furthermore, no deaths occurred during IBAP treatment, and no cases of aggravated GPB relapse were reported during the 12-month follow-up period. Conclusions. IBAP is a promising strategy for the treatment of GPB. Our findings demonstrated that IBAP had a noteworthy therapeutic effect, desirable safety, and ideal long-term efficacy for GPB.
机译：背景和目标。大多数肺大泡（GPB）患者均接受手术治疗。但是，对于某些亚群来说，手术是不可行的选择，例如那些有禁忌症的人或不愿接受手术的人。因此，对于该亚群，需要替代的微创方法。这项研究的目的是探索治疗GPB的替代程序。方法。这是一项前瞻性，非随机，单臂，无盲研究，评估了GPB患者的球内粘连性红斑病（IBAP）的有效性和安全性。该研究在2004年12月至2017年4月之间进行。结果。 36例患者中有38例（男33例，女3例），目标GPB腔的大小不等（范围10？cm×7？cm×5？cm至15？cm×8？cm×30？cm（前后）直径×内侧直径×上下直径））。 IBAP治疗后，GPB在一个月内的闭合率为86.84％（33/38），而呼吸困难指数从4.11±1.11显着降低至2.24±1.15（）。此外，平均FEV1（L）从1.06±0.73增加到1.57±1.13（），而RV（L）从2.77±0.54下降到2.36±0.38（），而TLC（L）从6.46±1.21下降到5.86± 1.08（）。此外，PaO2（mmHg）从52.18±8.31增加到68.29±12.34，而6 MWD从131.58±105.24增加到301.79±197.90（129.36％）。总的来说，这些数据表明IBAP治疗后肺功能和运动耐受性显着改善。此外，在IBAP治疗期间未发生死亡，在12个月的随访期间未报告GPB恶化的病例。结论。 IBAP是治疗GPB的有前途的策略。我们的发现表明，IBAP对GPB具有显着的治疗效果，理想的安全性和理想的长期疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号